A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
for Still´s Disease
2 locations incl. Cincinnati
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 1 - 100
Code: NCT07203001·Phase 2·Recruiting